By Stephen Nakrosis
Shares of blank-check company Newcourt Acquisition were trading higher on the Nasdaq on Wednesday, a day after the company's business combination target signed a securities purchase agreement for up to $10 million.
Shares of Newcourt were trading 17% higher shortly after noon EST, at $11.75 each. Volume at the time topped 55,000 shares, above the 65-day average volume of 1,861 shares.
On Tuesday, Psyence Biomedical Ltd., a subsidiary of Psyence Group Inc., said it signed the securities purchase agreement with a U.S.- based investment firm. The deal is expected to close concurrently or immediately prior to Psyence Biomedical's business combination with Newcourt, the subsidiary said. The SPAC deal will see Psyence Biomedical become a publicly traded company.
Psyence Group said it is "pioneering the use of natural psilocybin in mental health and well-being."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 17, 2024 13:15 ET (18:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。